Pharmaceutical companies are vying to lay out the "hyperglycemic" track, Class 1 new hypoglycemic drugs may welcome a major outbreak

Diabetes mellitus is a metabolic disease characterized by high blood sugar clinically, which can be specifically divided into type 1 diabetes, type 2 diabetes, and gestational diabetes
.
In recent years, as the aging of the population has increased, people’s living standards have continued to improve, and affected by poor life>
.
It is reported that in 2020, the market size of hypoglycemic drugs in China will exceed 52 billion yuan
.
Faced with a huge market, many pharmaceutical companies have begun to accelerate their deployment in the field of diabetes drugs
.
With the efforts of many companies, the research and development of new domestic hypoglycemic drugs has begun to have more new results
.
It is understood that since the beginning of this year, domestically produced Class 1 hypoglycemic new drugs have ushered in many new developments
.
According to incomplete statistics, there are currently more than 50 domestically produced Class 1 new hypoglycemic drugs in the clinical application and above stage, 14 of which have entered the phase III clinical and above stage, concentrated in DPP-4, GLP-1, and SGLT-2.
Big target
.
For example, on October 19, the original innovative drug "siglita sodium" independently developed and produced by Microchip Biosciences was approved for marketing by the National Medical Products Administration
.
According to its announcement, Siglipta Sodium is a new molecular entity drug with a novel mechanism discovered by Microchip Biosciences.
It is a new type of insulin sensitizer that has completed phase III clinical trials and has been declared for marketing (NDA) with type 2 diabetes as the indication.
Agent
.
Single medicine is suitable for diet control and exercise to improve blood sugar control in adults with type 2 diabetes
.
The analysis believes that the three major target hypoglycemic drugs of DPP-4, GLP-1, and SGLT-2 have their own characteristics and advantages, and the market prospects are full
.
Among them, the domestic market of DPP-4 is developing very rapidly
.
Including compound preparations, 10 DPP-4 inhibitors have been approved for marketing in China.
In 2020, the sales scale in China (Chinese public medical institutions and Chinese urban physical pharmacies, the same below) will be close to 4 billion yuan, of which SIG Liliptin sales exceeded 1 billion yuan, and saxagliptin sales approached 900 million yuan
.
It is worth noting that although there is currently no domestic DPP-4 inhibitor Class 1 new drug approved, many companies have already deployed
.
It is reported that there are currently 13 domestically-made Class 1 new drugs in the clinical and above stage of approval, and the research and development progress of companies such as Hengrui, Haisco, CSPC, and Xinlitai are ahead
.
In terms of GLP-1, including compound preparations, 9 GLP-1 receptor agonists have been approved for marketing in China (2 are domestically produced Class 1 new drugs).
In 2020, the domestic sales volume will exceed 1.
5 billion yuan.
Among them, the sales of liraglutide exceeded 1 billion yuan
.
In addition to the two domestically-made GLP-1 receptor agonists that have been approved for marketing, according to incomplete statistics, there are currently 17 domestically-made Class 1 new drugs in phase I and above
.
In addition, the SGLT-2 volume is also very obvious
.
Including compound preparations, 5 SGLT-2 inhibitors have been approved for marketing in China
.
In 2020, the domestic sales of SGLT-2 inhibitors will exceed 1 billion yuan, and it is expected to exceed 2 billion yuan in 2021, of which dapagliflozin will exceed 1 billion yuan
.
The data shows that although no domestic SGLT-2 inhibitor class 1 new drug has been approved yet, many companies have already deployed
.
Among them, 8 domestically produced Class 1 new drugs are at the stage of clinical approval and above, and the research and development progress of Hengrui, Dongyangguang Pharmaceutical and Xuanzhu Pharmaceutical is ahead
.
From an overall point of view, the industry believes that the "sugar reduction" track is highly sought after
.
The industry predicts that as more and more generic drugs are launched, and new drugs under research by local pharmaceutical companies are approved one after another, and the influence of policies such as centralized procurement and medical insurance negotiations are superimposed, the domestic diabetes market will continue to expand while it will continue to reshuffle
.